Effectiveness of Mirtazapine in the Treatment of Postherpetic Neuralgia

Journal of Pain and Symptom Management

Volumn 39, Issue 4, 2010, Pages e3-

  Christodoulou, Christos ^b   Douzenis, Athanassios ^b   Moussas, Georgios ^b   Lykouras, Lefteris ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; MIRTAZAPINE;

ADULT; ANKLE EDEMA; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LETTER; LOW DRUG DOSE; MAJOR DEPRESSION; MONOTHERAPY; NEUROPATHIC PAIN; PAIN ASSESSMENT; POSTHERPETIC NEURALGIA; TREATMENT DURATION;

EID: 77950900198     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2009.11.311     Document Type: Letter

References (20)

1. Kent J.M. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 355 (2000) 911-918
2. De Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 10 Suppl 4 (1995) 19-23
3. Nutt D. Treatment of cluster headache with mirtazapine. Headache 39 (1999) 586-587
4. Brannon G., Ronnald P., and Gary J. Use of mirtazapine as prophylactic treatment for migraine headache. Psychosomatics 41 (2000) 153-154
5. Bendtsen L., and Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology 62 (2004) 1706-1711
6. Theobald D.E., Kirsh K.L., Holtsclaw E., Donaghy K., and Passik S.D. An open-label, crossover trial of mirtazapine (15-30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 23 (2002) 442-447
7. Samborski W., Lezanska-Szpera M., and Rybakowski J.K. Open trial of mirtazapine inpatients with fibromyalgia. Pharmacopsychiatry 37 (2004) 168-170
8. Zhu J., Wei X., Feng X., et al. Repeated administration of mirtazapine inhibits development of hyperalgesia/allodynia and activation of NF-kappaB in a rat model of neuropathic pain. Neurosci Lett 433 (2008) 33-37
9. Freynhagen R., Muth-Selbach U., Lipfert P., et al. The effect of mirtazapine in patients with chronic pain and concomitant depression. Curr Med Res Opin 22 (2006) 257-264
10. Montgomery S. Safety of mirtazapine: a review. Int Clin Psychopharmacol 10 Suppl 4 (1995) 37-45
11. Remeron, product monograph. Available from. http://www.remeronrd.ca/en/Hcp/PDFs/RemeronRD_ProductMonograph.pdf Dec 2004
12. Zin C., Nissen L., Smith M., O'Callaghan J.P., and Moore B. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs 22 (2008) 417-442
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. [text revision] (2000), American Psychiatric Association, Washington, DC
14. Galer B., and Jensen M. Development and preliminary validation of a pain measure specific neuropathic pain: the Neuropathic Pain Scale. Neurology 48 (1997) 332-338
15. Harpaz R., Ortega-Sanchez I., and Seward J. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 57 RR-5 (2008) 1-30
16. Wu C., and Raja S. An update on the treatment of postherpetic neuralgia. J Pain 9 Suppl 1 (2008) S19-S30
17. Campayo J. Effectiveness of mirtazapine in the treatment of depression with associated somatic symptoms. Actas Esp Psiquiatr 36 (2008) 25-32
18. Arnold P., Vuadens P., Kuntzer T., Gobelet C., and Deriaz O. Mirtazapine decreases the pain feeling in healthy participants. Clin J Pain 24 (2008) 116-119
19. Brannon G., and Stone K. The use of mirtazapine in a patient with chronic pain. J Pain Symptom Manage 18 (1999) 382-385
20. Schreiber S., Rigai T., Katz Y., and Pick C. The antinociceptive effect of mirtazapine in mice is mediated through serotonergic, noradrenergic and opioid mechanisms. Brain Res Bull 58 (2002) 601-605